JPWO2019209715A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019209715A5
JPWO2019209715A5 JP2020559481A JP2020559481A JPWO2019209715A5 JP WO2019209715 A5 JPWO2019209715 A5 JP WO2019209715A5 JP 2020559481 A JP2020559481 A JP 2020559481A JP 2020559481 A JP2020559481 A JP 2020559481A JP WO2019209715 A5 JPWO2019209715 A5 JP WO2019209715A5
Authority
JP
Japan
Prior art keywords
cells
salt
hydroxycitric acid
isolated
cultured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521828A (ja
JP2021521828A5 (https=
JP7342030B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028513 external-priority patent/WO2019209715A1/en
Publication of JP2021521828A publication Critical patent/JP2021521828A/ja
Publication of JPWO2019209715A5 publication Critical patent/JPWO2019209715A5/ja
Publication of JP2021521828A5 publication Critical patent/JP2021521828A5/ja
Application granted granted Critical
Publication of JP7342030B2 publication Critical patent/JP7342030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559481A 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法 Active JP7342030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661941P 2018-04-24 2018-04-24
US62/661,941 2018-04-24
PCT/US2019/028513 WO2019209715A1 (en) 2018-04-24 2019-04-22 Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof

Publications (4)

Publication Number Publication Date
JP2021521828A JP2021521828A (ja) 2021-08-30
JPWO2019209715A5 true JPWO2019209715A5 (https=) 2022-05-02
JP2021521828A5 JP2021521828A5 (https=) 2022-05-02
JP7342030B2 JP7342030B2 (ja) 2023-09-11

Family

ID=66641471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559481A Active JP7342030B2 (ja) 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法

Country Status (7)

Country Link
US (2) US12415845B2 (https=)
EP (1) EP3784774B1 (https=)
JP (1) JP7342030B2 (https=)
CN (2) CN118726256A (https=)
AU (1) AU2019260656B2 (https=)
CA (1) CA3097858A1 (https=)
WO (1) WO2019209715A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004028A (ko) * 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022011129A1 (en) * 2020-07-09 2022-01-13 The Board Of Trustees Of The Leland Stanford University Multi-parallel analysis of t-cell therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
JP6378172B2 (ja) 2012-05-22 2018-08-22 アメリカ合衆国 マウス抗ny−eso−1t細胞受容体
IL286786B (en) 2012-09-14 2022-09-01 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst T cell receptors that recognize mhc mage–a3 are restricted type ii
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
AU2015209263A1 (en) 2014-01-24 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-NY-BR-1 polypeptides, proteins, and chimeric antigen receptors
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
JPWO2016067968A1 (ja) * 2014-10-29 2017-04-27 昭和電工株式会社 ミトコンドリア機能改善剤
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
US20190321314A1 (en) 2016-09-15 2019-10-24 Memorial Sloan Kettering Cancer Center Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders

Similar Documents

Publication Publication Date Title
Nallasamy et al. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis
Zhao et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Yuan et al. Cancer organoid co-culture model system: Novel approach to guide precision medicine
Abbasi et al. Mesenchymal stem cells and natural killer cells interaction mechanisms and potential clinical applications
Li et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
IL274293B2 (en) Process for generating therapeutic compositions of engineered cells
JP2024096899A5 (https=)
JP2021521828A5 (https=)
JP2016509840A5 (https=)
CA2133409A1 (en) Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
JPWO2018148566A5 (https=)
JP2021525519A5 (https=)
Lv et al. γδT cells, a key subset of T cell for cancer immunotherapy
Tyllis et al. CXCR5+ CD8+ T cells shape antibody responses in vivo following protein immunisation and peripheral viral infection
Fu et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells
JPWO2019209715A5 (https=)
Xiao et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
Rosenbaum et al. Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression
Zhang et al. A novel safer CD19CAR with shRNA interference of IFN-γ can reduce multiple cytokine levels without significantly compromising its killing efficacy
Yang et al. CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies
CN118726256A (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
Halim et al. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
JP7828098B2 (ja) T細胞をnk様細胞にリプログラミングする誘導剤およびその使用
CN114949192A (zh) 基因修饰car-t细胞在防止肿瘤复发中的应用
Pang et al. Contextualizing TH17 cells in cancer